Transgenic animal models for type II diabetes mellitus
    2.
    发明授权
    Transgenic animal models for type II diabetes mellitus 失效
    II型糖尿病的转基因动物模型

    公开(公告)号:US06187991B1

    公开(公告)日:2001-02-13

    申请号:US08446935

    申请日:1995-05-23

    IPC分类号: C12N1500

    摘要: The generation of transgenic animal models for testing various treatments of Type II Diabetes Mellitus are described. The DNA construct allows pancreatic &bgr; cell-specific expression of human islet associated polypeptide (IAPP) under the regulation of the rat insulin II promoter in both cell lines and transgenic animals. The DNA construct is introduced into animal embryos by microinjection as one or multiple copies or into established cell lines by electroporation. The transgenic animals develop amyloid plaque deposits in the islets of Langerhans in the pancreas, fasting hyperglycemia, glycouria and diabetic glomerulosclerosis at 3 to 5 months of age. The cell lines can be screened for treatments that inhibit expression of human IAPP; the transgenic animals can be screened for treatments that either enhance or inhibit the progression of this disease phenotype.

    摘要翻译: 描述了用于测试II型糖尿病各种治疗的转基因动物模型的产生。 该DNA构建体允许胰岛β细胞特异性表达人胰岛相关多肽(IAPP)在大鼠胰岛素II启动子的调节下在两种细胞系和转基因动物中。 通过显微注射将DNA构建体作为一个或多个拷贝引入动物胚胎,或通过电穿孔引入已建立的细胞系中。 转基因动物在3至5个月龄的胰腺胰岛胰岛,空腹高血糖症,糖尿病和糖尿病肾小球硬化胰岛中发生淀粉样斑块沉积。 可以筛选细胞系用于抑制人IAPP表达的治疗; 可以筛选转基因动物用于增强或抑制该疾病表现型进展的治疗。